Baylor Scott & White Health Research Institute, Institute for Immunology Research
The hollow fiber model of tuberculosis, which is a drug development tool now qualified by the European Medicine Agency and editorially endorsed by the FDA, was designed here in 2002. It is being used to design combination therapy regimens for TB that could shorten therapy to only a few weeks, down from a half-year or even longer in some cases. We are also working with this model to design the first drug regimen for children, and even newborns. http://www.biir.org
